詳細検索

詳細検索

お問い合わせ

Active Pharmaceutical Ingredients Market by Type, Synthesis, Potency, Product, Type of Drug, Application, Competition - Global forecast to 2031

Active Pharmaceutical Ingredients Market by Type, Synthesis, Potency, Product, Type of Drug, Application, Competition - Global forecast to 2031


The active pharmaceutical ingredients (API) market is expected to reach USD 199.42 billion in 2031 from USD 149.02 billion in 2026, at a CAGR of 6.0% during the forecast period. The market is prim... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年10月7日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
540
図表数
808
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

FIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & REGIONAL SCOPE 46.
FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED 47.
FIGURE 3 MARKET SCENARIO 50.
FIGURE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2024–2031 51.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2023–2026 51.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 52.
FIGURE 7 HIGH-GROWTH SEGMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2026–2031 53.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 54.
FIGURE 9 RISING DEMAND FOR INNOVATIVE, GENERIC, COMPLEX, AND BIOTECH APIS TO DRIVE MARKET GROWTH 55.
FIGURE 10 INNOVATIVE APIS ACCOUNTED FOR LARGEST SHARE OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN NORTH AMERICA IN 2025 56.
FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING FORECAST PERIOD 57.
FIGURE 12 TRADITIONAL APIS TO DOMINATE MARKET DURING FORECAST PERIOD 57.
FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58.
FIGURE 14 GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030 (USD BILLION) 61.
FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 70.
FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS 74.
FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS 75.
FIGURE 18 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,.
BY TYPE, 2025 77.
FIGURE 19 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,.
BY REGION, 2025 78.
FIGURE 20 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80.
FIGURE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT & FUNDING SCENARIO, 2025 (USD MILLION) 81.
FIGURE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES 91.
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 101.
FIGURE 24 KEY BUYING CRITERIA FOR END USERS 102.
FIGURE 25 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 256.
FIGURE 26 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 311.
FIGURE 27 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2025 (USD MILLION) 408.
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2025 409.
FIGURE 29 EV/EBITDA OF KEY VENDORS 411.
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 412.
FIGURE 31 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON 413.
FIGURE 32 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 415.
FIGURE 33 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT 416.
FIGURE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 422.
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2025) 429.
FIGURE 36 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2025) 432.
FIGURE 37 ASYMCHEM INC.: COMPANY SNAPSHOT (2025) 438.
FIGURE 38 CIPLA: COMPANY SNAPSHOT (2025) 442.
FIGURE 39 EVONIK: COMPANY SNAPSHOT (2025) 447.
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 451.
FIGURE 41 SANDOZ GROUP AG: COMPANY SNAPSHOT (2025) 462.
FIGURE 42 SK INC.: COMPANY SNAPSHOT (2025) 467.
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 470.
FIGURE 44 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2025) 473.
FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 477.
FIGURE 46 AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2025) 481.
FIGURE 47 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 484.
FIGURE 48 BASF: COMPANY SNAPSHOT (2025) 487.
FIGURE 49 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2025) 490.
FIGURE 50 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2025) 493.
FIGURE 51 EUROAPI: COMPANY SNAPSHOT (2025) 496.
FIGURE 52 BACHEM: COMPANY SNAPSHOT (2025) 500.
FIGURE 53 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN 520.
FIGURE 54 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF PRIMARIES 522.
FIGURE 55 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INSIGHTS FROM PRIMARIES 523.
FIGURE 56 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ESTIMATION, 2025 524.
FIGURE 57 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 525.
FIGURE 58 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE ANALYSIS (2025) 525.
FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 527.
FIGURE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS 528.
FIGURE 61 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION 529.
TABLE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS & EXCLUSIONS 47.
TABLE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 59.
TABLE 3 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2024 62.
TABLE 4 EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024 63.
TABLE 5 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,.
2023–2030 (USD BILLION) 68.
TABLE 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES 70.
TABLE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM 75.
TABLE 8 INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER, 2025 (USD) 77.
TABLE 9 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,.
BY REGION, 2025 (USD) 78.
TABLE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 79.
TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS 82.
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 83.
TABLE 13 KEY COMPANIES IMPLEMENTING AI 92.
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94.
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94.
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95.
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95.
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 96.
TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 102.
TABLE 20 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER 103.
TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,.
2023–2031 (USD BILLION) 107.
TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 107.
TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,.
2023–2031 (USD BILLION) 108.
TABLE 24 INNOVATIVE APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 109.
TABLE 25 NORTH AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 109.
TABLE 26 EUROPE: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110.
TABLE 27 ASIA PACIFIC: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110.
TABLE 28 LATIN AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 111.
TABLE 29 MIDDLE EAST: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 111.
TABLE 30 GCC COUNTRIES: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 111.
TABLE 31 GENERIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 112.
TABLE 32 NORTH AMERICA: GENERIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 113.
TABLE 33 EUROPE: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 113.
TABLE 34 ASIA PACIFIC: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114.
TABLE 35 LATIN AMERICA: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114.
TABLE 36 MIDDLE EAST: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114.
TABLE 37 GCC COUNTRIES: GENERIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 115.
TABLE 38 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,.
2023–2031 (USD BILLION) 117.
TABLE 39 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 117.
TABLE 40 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,.
2023–2031 (USD BILLION) 118.
TABLE 41 TRADITIONAL APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 119.
TABLE 42 NORTH AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 119.
TABLE 43 EUROPE: TRADITIONAL APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 120.
TABLE 44 ASIA PACIFIC: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 120.
TABLE 45 LATIN AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 121.
TABLE 46 MIDDLE EAST: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 121.
TABLE 47 GCC COUNTRIES: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 121.
TABLE 48 HIGHLY POTENT APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 122.
TABLE 49 HIGHLY POTENT APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 122.
TABLE 50 NORTH AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 123.
TABLE 51 EUROPE: HIGHLY POTENT APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 123.
TABLE 52 ASIA PACIFIC: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 124.
TABLE 53 LATIN AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 124.
TABLE 54 MIDDLE EAST: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 124.
TABLE 55 GCC COUNTRIES: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 125.
TABLE 56 SYNTHETIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 126.
TABLE 57 NORTH AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 126.
TABLE 58 EUROPE: SYNTHETIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 127.
TABLE 59 ASIA PACIFIC: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 127.
TABLE 60 LATIN AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 128.
TABLE 61 MIDDLE EAST: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 128.
TABLE 62 GCC COUNTRIES: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 128.
TABLE 63 BIOLOGIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 129.
TABLE 64 NORTH AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 130.
TABLE 65 EUROPE: BIOLOGIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 130.
TABLE 66 ASIA PACIFIC: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 131.
TABLE 67 LATIN AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 131.
TABLE 68 MIDDLE EAST: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 131.
TABLE 69 GCC COUNTRIES: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 132.
TABLE 70 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,.
2023–2031 (USD BILLION) 134.
TABLE 71 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 134.
TABLE 72 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2031 (USD BILLION) 135.
TABLE 73 SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 136.
TABLE 74 NORTH AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 136.
TABLE 75 EUROPE: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137.
TABLE 76 ASIA PACIFIC: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137.
TABLE 77 LATIN AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 138.
TABLE 78 MIDDLE EAST: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 138.
TABLE 79 GCC COUNTRIES: SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 138.
TABLE 80 SYNTHETIC APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 139.
TABLE 81 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 140.
TABLE 82 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 140.
TABLE 83 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 141.
TABLE 84 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 141.
TABLE 85 LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 142.
TABLE 86 MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 142.
TABLE 87 GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 142.
TABLE 88 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 143.
TABLE 89 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 143.
TABLE 90 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 144.
TABLE 91 ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 144.
TABLE 92 LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 145.
TABLE 93 MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 145.
TABLE 94 GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 145.
TABLE 95 BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 146.
TABLE 96 NORTH AMERICA: BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 147.
TABLE 97 EUROPE: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 147.
TABLE 98 ASIA PACIFIC: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148.
TABLE 99 LATIN AMERICA: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148.
TABLE 100 MIDDLE EAST: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148.
TABLE 101 GCC COUNTRIES: BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 149.
TABLE 102 BIOTECH APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 149.
TABLE 103 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 150.
TABLE 104 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 150.
TABLE 105 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 151.
TABLE 106 ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 151.
TABLE 107 LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 152.
TABLE 108 MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 152.
TABLE 109 GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 152.
TABLE 110 GENERIC BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 154.
TABLE 111 NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 154.
TABLE 112 EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 155.
TABLE 113 ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 155.
TABLE 114 LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 156.
TABLE 115 MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 156.
TABLE 116 GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 156.
TABLE 117 BIOTECH APIS MARKET, BY PRODUCT, 2023–2031 (USD BILLION) 157.
TABLE 118 BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,.
2023–2031 (USD BILLION) 158.
TABLE 119 NORTH AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 158.
TABLE 120 EUROPE: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD BILLION) 159.
TABLE 121 ASIA PACIFIC: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 159.
TABLE 122 LATIN AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 160.
TABLE 123 MIDDLE EAST: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 160.
TABLE 124 GCC COUNTRIES: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 160.
TABLE 125 BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2023–2031 (USD BILLION) 161.
TABLE 126 NORTH AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 161.
TABLE 127 EUROPE: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,.
BY COUNTRY, 2023–2031 (USD BILLION) 162.
TABLE 128 ASIA PACIFIC: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,.
BY COUNTRY, 2023–2031 (USD BILLION) 162.
TABLE 129 LATIN AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163.
TABLE 130 MIDDLE EAST: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,.
BY COUNTRY, 2023–2031 (USD BILLION) 163.
TABLE 131 GCC COUNTRIES: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163.
TABLE 132 BIOTECH APIS MARKET FOR FUSION PROTEINS, BY REGION,.
2023–2031 (USD BILLION) 164.
TABLE 133 NORTH AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 164.
TABLE 134 EUROPE: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY,.
2023–2031 (USD BILLION) 165.
TABLE 135 ASIA PACIFIC: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 165.
TABLE 136 LATIN AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166.
TABLE 137 MIDDLE EAST: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166.
TABLE 138 GCC COUNTRIES: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166.
TABLE 139 BIOTECH APIS MARKET FOR CYTOKINES, BY REGION, 2023–2031 (USD BILLION) 167.
TABLE 140 NORTH AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 167.
TABLE 141 EUROPE: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 168.
TABLE 142 ASIA PACIFIC: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 168.
TABLE 143 LATIN AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 169.
TABLE 144 MIDDLE EAST: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 169.
TABLE 145 GCC COUNTRIES: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 169.
TABLE 146 BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY REGION,.
2023–2031 (USD BILLION) 170.
TABLE 147 NORTH AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,.
BY COUNTRY, 2023–2031 (USD BILLION) 170.
TABLE 148 EUROPE: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171.
TABLE 149 ASIA PACIFIC: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171.
TABLE 150 LATIN AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,.
BY COUNTRY, 2023–2031 (USD BILLION) 172.
TABLE 151 MIDDLE EAST: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 172.
TABLE 152 GCC COUNTRIES: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,.
BY COUNTRY, 2023–2031 (USD BILLION) 172.
TABLE 153 BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY REGION, 2023–2031 (USD BILLION) 173.
TABLE 154 NORTH AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 173.
TABLE 155 EUROPE: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS,.
BY COUNTRY, 2023–2031 (USD BILLION) 174.
TABLE 156 ASIA PACIFIC: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 174.
TABLE 157 LATIN AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175.
TABLE 158 MIDDLE EAST: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175.
TABLE 159 GCC COUNTRIES: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175.
TABLE 160 BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY REGION,.
2023–2031 (USD BILLION) 176.
TABLE 161 NORTH AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 177.
TABLE 162 EUROPE: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 177.
TABLE 163 ASIA PACIFIC: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 178.
TABLE 164 LATIN AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 178.
TABLE 165 MIDDLE EAST: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 179.
TABLE 166 GCC COUNTRIES: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 179.
TABLE 167 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM, 2023–2031 (USD BILLION) 180.
TABLE 168 BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 181.
TABLE 169 NORTH AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 181.
TABLE 170 EUROPE: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 182.
TABLE 171 ASIA PACIFIC: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 182.
TABLE 172 LATIN AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183.
TABLE 173 MIDDLE EAST: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183.
TABLE 174 GCC COUNTRIES: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183.
TABLE 175 BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 184.
TABLE 176 NORTH AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 185.
TABLE 177 EUROPE: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 185.
TABLE 178 ASIA PACIFIC: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 186.
TABLE 179 LATIN AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 186.
TABLE 180 MIDDLE EAST: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 187.
TABLE 181 GCC COUNTRIES: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 187.
TABLE 182 BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION,.
2023–2031 (USD BILLION) 188.
TABLE 183 NORTH AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 188.
TABLE 184 EUROPE: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 189.
TABLE 185 ASIA PACIFIC: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 189.
TABLE 186 LATIN AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 190.
TABLE 187 MIDDLE EAST: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 190.
TABLE 188 GCC COUNTRIES: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 190.
TABLE 189 BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION,.
2023–2031 (USD BILLION) 192.
TABLE 190 NORTH AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 192.
TABLE 191 EUROPE: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 193.
TABLE 192 ASIA PACIFIC: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 193.
TABLE 193 LATIN AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 194.
TABLE 194 MIDDLE EAST: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 194.
TABLE 195 GCC COUNTRIES: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 194.
TABLE 196 BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION,.
2023–2031 (USD BILLION) 195.
TABLE 197 NORTH AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 195.
TABLE 198 EUROPE: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 196.
TABLE 199 ASIA PACIFIC: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 196.
TABLE 200 LATIN AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 197.
TABLE 201 MIDDLE EAST: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 197.
TABLE 202 GCC COUNTRIES: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 197.
TABLE 203 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,.
2023–2031 (USD BILLION) 199.
TABLE 204 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 199.
TABLE 205 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2031 (USD BILLION) 200.
TABLE 206 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS,.
BY REGION, 2023–2031 (USD BILLION) 201.
TABLE 207 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 201.
TABLE 208 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202.
TABLE 209 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202.
TABLE 210 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203.
TABLE 211 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203.
TABLE 212 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203.
TABLE 213 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2031 (USD BILLION) 204.
TABLE 214 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205.
TABLE 215 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205.
TABLE 216 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206.
TABLE 217 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206.
TABLE 218 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207.
TABLE 219 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207.
TABLE 220 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 209.
TABLE 221 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 210.
TABLE 222 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 210.
TABLE 223 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2031 (USD BILLION) 211.
TABLE 224 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212.
TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212.
TABLE 226 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213.
TABLE 227 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213.
TABLE 228 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214.
TABLE 229 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214.
TABLE 230 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER 215.
TABLE 231 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2023–2031 (USD BILLION) 215.
TABLE 232 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 216.
TABLE 233 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,.
BY COUNTRY, 2023–2031 (USD BILLION) 216.
TABLE 234 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217.
TABLE 235 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217.
TABLE 236 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218.
TABLE 237 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218.
TABLE 238 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2023–2031 (USD BILLION) 219.
TABLE 239 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 219.
TABLE 240 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,.
BY COUNTRY, 2023–2031 (USD BILLION) 220.
TABLE 241 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 220.
TABLE 242 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221.
TABLE 243 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221.
TABLE 244 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221.
TABLE 245 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD BILLION) 222.
TABLE 246 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223.
TABLE 247 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223.
TABLE 248 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224.
TABLE 249 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224.
TABLE 250 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225.
TABLE 251 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225.
TABLE 252 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2031 (USD BILLION) 226.
TABLE 253 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 226.
TABLE 254 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227.
TABLE 255 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227.
TABLE 256 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228.
TABLE 257 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228.
TABLE 258 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228.
TABLE 259 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT,.
BY REGION, 2023–2031 (USD BILLION) 229.
TABLE 260 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230.
TABLE 261 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230.
TABLE 262 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231.
TABLE 263 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231.
TABLE 264 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232.
TABLE 265 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232.
TABLE 266 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2031 (USD BILLION) 233.
TABLE 267 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD BILLION) 233.

 

ページTOPに戻る


 

Summary

The active pharmaceutical ingredients (API) market is expected to reach USD 199.42 billion in 2031 from USD 149.02 billion in 2026, at a CAGR of 6.0% during the forecast period. The market is primarily driven by the rapid growth of oncology and rare disease pipelines, increasing development of targeted and specialty therapies, rising demand for complex and high-potency APIs (HPAPIs), and growing pharmaceutical research and development activities. The expansion of oncology and rare disease drug pipelines is increasing demand for APIs used in innovative therapies, including highly potent molecules, biologics, peptides, and other complex drug substances. These APIs support the development and manufacturing of therapies across cancer, genetic disorders, and other rare and complex diseases. In addition, the increasing adoption of precision medicine and targeted therapies is driving demand for specialized API manufacturing capabilities, particularly for complex molecules and HPAPIs. Growing investments by pharmaceutical companies in drug discovery, clinical development, and commercial manufacturing are further supporting API demand. However, market growth continues to be challenged by stringent regulatory requirements, high production and development costs, supply chain vulnerabilities, and the specialized infrastructure required for the manufacturing and handling of complex and highly potent APIs.

Innovative API segment to grow at the highest CAGR during forecast period
The innovative segment is projected to grow at the highest CAGR in the active pharmaceutical ingredients (API) market due to the increasing development of novel therapies, rising prevalence of complex diseases, and expansion of oncology and rare disease drug pipelines. Innovative APIs are increasingly required for the development of targeted and specialty medicines, particularly those involving complex molecules and advanced therapeutic approaches. The growing focus on precision medicine and increasing pharmaceutical R&D activities are further driving demand for innovative APIs across oncology, rare diseases, immunology, and other therapeutic areas. In addition, the increasing number of clinical-stage and commercial innovative medicines is supporting demand for specialized API development and manufacturing capabilities.

Synthetic API segment holds largest share of the market
The synthetic segment accounts for the largest share of the active pharmaceutical ingredients (API) market, driven by the increasing use of synthetic APIs in the development and manufacturing of generic and innovative medicines across various therapeutic areas. Synthetic API manufacturing plays a critical role in the production of small-molecule drugs, supporting applications in oncology, cardiovascular diseases, diabetes, respiratory diseases, and infectious diseases. The growing demand for cost-effective medicines, along with established manufacturing infrastructure, scalable production processes, and advances in synthetic chemistry, continues to strengthen the position of this segment.

US to grow at highest CAGR during forecast period
The US is expected to grow at the highest CAGR in the active pharmaceutical ingredients (API) market due to its strong presence of leading pharmaceutical and biotechnology companies, advanced drug development infrastructure, and high demand for innovative and complex APIs. Rising development of oncology and rare disease therapies, increasing adoption of high-potency APIs (HPAPIs), and growing investments in domestic pharmaceutical manufacturing are key factors driving market growth. Technologies and capabilities such as advanced synthesis, continuous manufacturing, process automation, and high-containment manufacturing are increasingly adopted by pharmaceutical companies, biotechnology firms, and CDMOs, further supporting demand for API manufacturing in the US.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side – 70% and Demand Side– 30%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%

Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi's Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy's Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma Limited (India), Evonik (Germany), Hikma Pharmaceuticals plc (UK), BASF (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem Inc. (China), Bachem (Switzerland), and Zhejiang Huahai Pharmaceutical Co., Ltd. (China) are some of the key companies offering products in the active pharmaceutical ingredients (API) market.

Research Coverage
This research report categorizes the active pharmaceutical ingredient market by type (innovative and generics), potency (traditional API and HPAPI [synthetic and biologics]), synthesis (synthetic [innovative and generics] and biotech [by type {innovative and generic}, by product {monoclonal antibodies, hormones and growth factors, fusion proteins, cytokines, therapeutic enzymes, blood factors & anti-coagulants and recombinant vaccines} and by expression system {mammalian expression systems, microbial expression systems, yeast expression systems, insect expression systems, and other expression system}]), type of drug (prescription and over the counter), therapeutic application (communicable diseases, oncology, diabetes, cardiovascular diseases, respiratory diseases, pain management and other therapeutic applications), end user (pharmaceutical & biotechnology industry, contract research organization, contract manufacturing organizations, and others), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the active pharmaceutical ingredients (API) market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to active pharmaceutical ingredients (API) market. This report also includes a competitive analysis of emerging startups in the active pharmaceutical ingredients (API) industry ecosystem.

Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:
- Analysis of key drivers (Surge in demand for complex APIs, Government incentives and supply chain reshoring, Increasing adoption of continuous manufacturing and digital process controls, Rapid growth of oncology and rare disease pipelines), restraints (Tightening regulatory requirements for nitrosamine and impurity controls, High production costs in US and Europe based facilities, Price pressure from generic tenders and single-winner procurement policies), opportunities (Growing emphasis on supply resilience and security of critical medicines, China-Plus-One Strategy, Increasing adoption of integrated service models), and challenges (Capital-intensive investments for high containment and advanced facilities, Quality failures and site shutdowns, Supply chain concentration risk, Geopolitical tensions and trade restrictions) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the active pharmaceutical ingredients (API) market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the active pharmaceutical ingredients (API) market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, such as Pfizer Inc. (US), Divi's Laboratories Limited (India), Asymchem Inc. (China), Cipla (India), Evonik (Germany), among others, for the active pharmaceutical ingredient (API) market



ページTOPに戻る


Table of Contents

1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION 45
1.3 STUDY SCOPE 45
1.3.1 SEGMENTS CONSIDERED & REGIONAL SCOPE 46
1.3.2 INCLUSIONS & EXCLUSIONS 47
1.3.3 YEARS CONSIDERED 47
1.4 CURRENCY CONSIDERED 48
1.5 STAKEHOLDERS 48
1.6 SUMMARY OF CHANGES 48

2 EXECUTIVE SUMMARY 50
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 50
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 51
2.3 DISRUPTIVE TRENDS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 52
2.4 HIGH-GROWTH SEGMENTS 53
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 54

3 PREMIUM INSIGHTS 55
3.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW 55
3.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY SERVICE 56
3.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57
3.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY POTENCY,

2026 VS 2031 (%) 57

4 MARKET OVERVIEW 58
4.1 INTRODUCTION 58
4.2 MARKET DYNAMICS 58
4.2.1 DRIVERS 60
4.2.1.1 Surge in demand for complex APIs 60
4.2.1.2 Favorable government incentives and supply chain reshoring 60
4.2.1.3 Increasing adoption of continuous manufacturing and digital process controls 61
4.2.1.4 Rapid growth of oncology and rare disease pipelines 62
4.2.2 RESTRAINTS 63
4.2.2.1 Tightening regulatory requirements for nitrosamine and impurity controls 63
4.2.2.2 High production costs in US- and Europe-based facilities 64
4.2.2.3 Price pressure from generic tenders and single-winner procurement policies 64
4.2.3 OPPORTUNITIES 64
4.2.3.1 Growing emphasis on supply resilience and security of critical medicine manufacturing 64
4.2.3.2 China-Plus-One strategy 65
4.2.3.3 Increasing adoption of integrated CDMO service models 65
4.2.4 CHALLENGES 66
4.2.4.1 Capital-intensive investments for high-containment and advanced facilities 66
4.2.4.2 Quality failures and site shutdowns 66
4.2.4.3 Supply chain concentration risk 66
4.2.4.4 Geopolitical tensions and trade restrictions 66
4.3 UNMET NEEDS & WHITE SPACES 67
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 67
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 68

5 INDUSTRY TRENDS 70
5.1 PORTER’S FIVE FORCES ANALYSIS 70
5.1.1 THREAT OF NEW ENTRANTS 71
5.1.2 THREAT OF SUBSTITUTES 71
5.1.3 BARGAINING POWER OF SUPPLIERS 71
5.1.4 BARGAINING POWER OF BUYERS 71
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.2 MACROECONOMIC OUTLOOK 72
5.2.1 INTRODUCTION 72
5.2.2 GDP TRENDS & FORECAST 72
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 72
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY 73
5.3 VALUE CHAIN ANALYSIS 73
5.3.1 RESEARCH & DEVELOPMENT (VALUE ADDITION: 30–35%) 74
5.3.2 CLINICAL TRIALS & REGULATORY APPROVALS (VALUE ADDITION: 50–70%) 74
5.3.3 MANUFACTURING (VALUE ADDITION: 70–80%) 74
5.3.4 MARKETING & COMMERCIALIZATION (VALUE ADDITION: 80–100%) 75
5.4 ECOSYSTEM ANALYSIS 75
5.5 PRICING ANALYSIS 76
5.5.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2025 76
5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 78
5.6 KEY CONFERENCES & EVENTS, 2026–2027 79
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
5.8 INVESTMENT & FUNDING SCENARIO 81
5.9 CASE STUDY ANALYSIS 82
5.10 IMPACT OF 2025 US TARIFFS ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 82
5.10.1 INTRODUCTION 82
5.10.2 KEY TARIFF RATES 83
5.10.3 PRICE IMPACT ANALYSIS 84
5.10.4 IMPACT ON COUNTRY/REGION 84
5.10.4.1 North America 84
5.10.4.1.1 US 84
5.10.4.2 Europe 84
5.10.4.3 Asia Pacific 85
5.10.5 IMPACT ON END-USE INDUSTRIES 85
5.10.5.1 Pharmaceutical & biotechnology industry 85
5.10.5.2 Contract research organizations (CROs) 85
5.10.5.3 Contract manufacturing organizations (CMOs) 85

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 KEY TECHNOLOGIES 86
6.1.1 CONTINUOUS MANUFACTURING 86
6.1.2 ADVANCED ANALYTICAL TECHNIQUES 86
6.1.3 BIOCATALYSIS 86
6.2 COMPLEMENTARY TECHNOLOGIES 87
6.2.1 DATA ANALYTICS & DIGITALIZATION 87
6.2.2 PERSONALIZED MEDICINES & CUSTOM SYNTHESIS 87
6.2.3 SUPERCRITICAL FLUID TECHNOLOGY 87
6.3 ADJACENT TECHNOLOGIES 88
6.3.1 SUPPLY CHAIN VISIBILITY & BLOCKCHAIN 88
6.3.2 3D PRINTING 88
6.3.3 NANOTECHNOLOGY 88
6.4 TECHNOLOGY ROADMAP 89
6.5 FUTURE APPLICATIONS 89
6.6 IMPACT OF AI/GEN AI ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 90
6.6.1 INTRODUCTION 90
6.6.2 IMPACT AND MARKET POTENTIAL OF ARTIFICIAL INTELLIGENCE IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 90
6.6.3 AI USE CASES 91
6.6.4 FUTURE OF GENERATIVE AI IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ECOSYSTEM 93

7 SUSTAINABILITY & REGULATORY LANDSCAPE 94
7.1 REGIONAL REGULATIONS & COMPLIANCE 94
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS 94
7.1.2 INDUSTRY STANDARDS 96
7.2 SUSTAINABILITY INITIATIVES 97
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 97
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 97

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101
8.1 DECISION-MAKING PROCESS 101
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 101
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
8.2.2 KEY BUYING CRITERIA 102
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 104
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 104

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 106
9.1 INTRODUCTION 107
9.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT) 107
9.3 INNOVATIVE APIS 108
9.3.1 INCREASING REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO FACILITATE GROWTH 108
9.4 GENERIC APIS 112
9.4.1 GROWING FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET 112

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 116
10.1 INTRODUCTION 117
10.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY POTENCY (CAPTIVE AND MERCHANT) 117
10.3 TRADITIONAL APIS 118
10.3.1 INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO AUGMENT GROWTH 118
10.4 HIGHLY POTENT APIS 122
10.4.1 SYNTHETIC HPAPIS 125
10.4.1.1 Evolving targeted oncology therapies to stimulate growth 125
10.4.2 BIOLOGIC HPAPIS 129
10.4.2.1 Robust product pipeline to encourage growth 129

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 133
11.1 INTRODUCTION 134
11.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT) 134
11.3 SYNTHETIC APIS 135
11.3.1 SYNTHETIC APIS MARKET, BY TYPE 139
11.3.2 INNOVATIVE SYNTHETIC APIS 139
11.3.2.1 High value of innovative APIs to drive market 139
11.3.3 GENERIC SYNTHETIC APIS 143
11.3.3.1 Increasing need for generic medicines to contribute to growth 143
11.4 BIOTECH APIS 146
11.4.1 BIOTECH APIS MARKET, BY TYPE 149
11.4.1.1 Innovative biotech APIs 149
11.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market 149
11.4.1.2 Generic biotech APIs 153
11.4.1.2.1 Cost-effectiveness and favorable government efforts to fuel market 153
11.4.2 BIOTECH APIS MARKET, BY PRODUCT 157
11.4.2.1 Monoclonal antibodies 157
11.4.2.1.1 Growing applications of antibody-drug conjugates in treating cancer to drive market 157
11.4.2.2 Hormones & growth factors 161
11.4.2.2.1 Growing incidence of hormonal disorders to drive market 161
11.4.2.3 Fusion proteins 164
11.4.2.3.1 Increasing applications of fusion proteins in biopharmaceuticals to aid growth 164
11.4.2.4 Cytokines 167
11.4.2.4.1 Rising use of cytokines in cell signaling, inflammation, and cell growth to spur growth 167
11.4.2.5 Therapeutic enzymes 170
11.4.2.5.1 Growing significance of enzymes in therapies for cancer and pain management to propel market 170
11.4.2.6 Blood factors & anticoagulants 173
11.4.2.6.1 Growing incidence of hemophilia to fuel market 173
11.4.2.7 Recombinant vaccines 176
11.4.2.7.1 Growing prevalence of infectious diseases to fuel market 176
11.4.3 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM 179
11.4.3.1 Mammalian expression systems 180
11.4.3.1.1 Ability to carry out post-translational modifications to drive adoption 180
11.4.3.2 Microbial expression systems 184
11.4.3.2.1 High expression levels of proteins at low costs to aid growth 184
11.4.3.3 Yeast expression systems 187
11.4.3.3.1 Efficient protein secretion and simple purification to contribute to growth 187
11.4.3.4 Insect expression systems 191
11.4.3.4.1 Scalability, cost-effectiveness, and favorable safety profile to boost market 191
11.4.3.5 Other expression systems 195

12 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 198
12.1 INTRODUCTION 199
12.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF DRUG (CAPTIVE AND MERCHANT) 199
12.3 PRESCRIPTION DRUGS 200
12.3.1 INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT GROWTH 200
12.4 OVER-THE-COUNTER DRUGS 204
12.4.1 RISING AWARENESS OF PRECAUTIONARY CARE AND HEALTH CONCERNS TO SPUR GROWTH 204

13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 208
13.1 INTRODUCTION 209
13.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT) 209
13.3 COMMUNICABLE DISEASES 211
13.3.1 INCREASING INVESTMENTS IN DEVELOPING NEW ANTIBIOTICS, ANTIVIRALS, ANTIFUNGALS, AND VACCINES TO AID GROWTH 211
13.4 ONCOLOGY 214
13.4.1 GROWING NUMBER OF FDA APPROVALS TO DRIVE MARKET 214
13.5 DIABETES 218
13.5.1 RISING ADVANCEMENTS IN TREATMENT OPTIONS TO EXPEDITE GROWTH 218
13.6 CARDIOVASCULAR DISEASES 222
13.6.1 INCREASING ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS TO PROMOTE GROWTH 222
13.7 RESPIRATORY DISEASES 225
13.7.1 INCREASING BURDEN OF RESPIRATORY DISORDERS TO BOLSTER GROWTH 225
13.8 PAIN MANAGEMENT 229
13.8.1 RISING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO BOLSTER GROWTH 229
13.9 OTHER THERAPEUTIC APPLICATIONS 232

14 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER 236
14.1 INTRODUCTION 237
14.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER (CAPTIVE AND MERCHANT) 237
14.3 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 238
14.3.1 RISE IN NEED OF NOVEL TREATMENTS TO EXPEDITE GROWTH 238
14.4 CONTRACT RESEARCH ORGANIZATIONS 242
14.4.1 INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT GROWTH 242
14.5 CONTRACT MANUFACTURING ORGANIZATIONS 246
14.5.1 GROWING FOCUS ON BETTER QUALITY AND REGULATORY COMPLIANCE TO DRIVE MARKET 246
14.6 OTHER END USERS 249

15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 253
15.1 INTRODUCTION 254
15.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT) 254
15.3 NORTH AMERICA 255
15.3.1 US 261
15.3.1.1 High clinical trial & drug discovery activity and efficient regulatory environment to expedite growth 261
15.3.2 CANADA 267
15.3.2.1 Favorable government support and strong product pipeline to sustain growth 267
15.4 EUROPE 272
15.4.1 GERMANY 277
15.4.1.1 High healthcare expenditure and advanced R&D facilities to drive market 277
15.4.2 UK 282
15.4.2.1 Rising government investments and growing focus on personalized treatment to fuel market 282
15.4.3 FRANCE 287
15.4.3.1 Increased focus on domestic manufacturing to promote growth 287
15.4.4 ITALY 291
15.4.4.1 Rising commercial drug development to favor growth 291
15.4.5 SPAIN 296
15.4.5.1 Increase in generic drug manufacturing capacity to propel market 296
15.4.6 HUNGARY 301
15.4.6.1 Increasing manufacturing activities in pharmaceutical sector to drive market 301
15.4.7 REST OF EUROPE 305
15.5 ASIA PACIFIC 311
15.5.1 CHINA 316
15.5.1.1 Rise in government policies to increase medicine access and affordability to support growth 316
15.5.2 JAPAN 321
15.5.2.1 Growing geriatric population to boost market 321
15.5.3 INDIA 326
15.5.3.1 Increasing R&D activities and rising government funding initiatives to favor growth 326
15.5.4 SOUTH KOREA 331
15.5.4.1 Rising annual drug exports to drive market 331
15.5.5 AUSTRALIA 336
15.5.5.1 Increasing demand for innovative APIs to propel market 336
15.5.6 REST OF ASIA PACIFIC 341
15.6 LATIN AMERICA 346
15.6.1 BRAZIL 351
15.6.1.1 Increased government investments in pharmaceutical R&D to drive market 351
15.6.2 MEXICO 356
15.6.2.1 Rising investments by foreign firms to support market growth 356
15.6.3 REST OF LATIN AMERICA 361
15.7 MIDDLE EAST 366
15.7.1 ISRAEL 371
15.7.1.1 Highly educated workforce and strong culture of innovation to support growth 371
15.7.2 GCC COUNTRIES 376
15.7.2.1 Saudi Arabia 381
15.7.2.1.1 Growing healthcare expenditure to boost market 381
15.7.2.2 UAE 386
15.7.2.2.1 Rising demand for technologically advanced manufacturing processes to aid growth 386
15.7.2.3 Rest of GCC Countries 390
15.7.3 REST OF MIDDLE EAST 396
15.8 AFRICA 400
15.8.1 GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET 400

16 COMPETITIVE LANDSCAPE 406
16.1 INTRODUCTION 406
16.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 406
16.3 REVENUE ANALYSIS, 2022–2025 408
16.4 MARKET SHARE ANALYSIS, 2025 409
16.5 COMPANY VALUATION & FINANCIAL METRICS 411
16.5.1 FINANCIAL METRICS 411
16.5.2 COMPANY VALUATION 411
16.6 BRAND/PRODUCT COMPARISON 412
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 414
16.7.1 STARS 414
16.7.2 EMERGING LEADERS 414
16.7.3 PERVASIVE PLAYERS 414
16.7.4 PARTICIPANTS 414
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 416
16.7.5.1 Company footprint 416
16.7.5.2 Region footprint 417
16.7.5.3 Type footprint 418
16.7.5.4 Potency footprint 419
16.7.5.5 Therapeutic application footprint 420
16.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 421
16.8.1 PROGRESSIVE COMPANIES 421
16.8.2 RESPONSIVE COMPANIES 421
16.8.3 DYNAMIC COMPANIES 422
16.8.4 STARTING BLOCKS 422
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 423
16.8.5.1 Detailed list of key startups/SMEs 423
16.8.5.2 Competitive benchmarking of key startups/SMEs 424
16.9 COMPETITIVE SCENARIO 425
16.9.1 PRODUCT APPROVALS 425
16.9.2 DEALS 425
16.9.3 EXPANSIONS 426

17 COMPANY PROFILES 428
17.1 KEY PLAYERS 428
17.1.1 PFIZER INC. 428
17.1.1.1 Business overview 428
17.1.1.2 Products offered 429
17.1.1.3 Recent developments 430
17.1.1.3.1 Deals 430
17.1.1.3.2 Expansions 431
17.1.1.3.3 Other developments 431
17.1.1.4 MnM view 431
17.1.1.4.1 Key strengths 431
17.1.1.4.2 Strategic choices 431
17.1.1.4.3 Weaknesses & competitive threats 431
17.1.2 DIVI’S LABORATORIES LIMITED 432
17.1.2.1 Business overview 432
17.1.2.2 Products offered 433
17.1.2.3 Recent developments 434
17.1.2.3.1 Deals 434
17.1.2.3.2 Expansions 435
17.1.2.3.3 Other developments 436
17.1.2.4 MnM view 436
17.1.2.4.1 Key strengths 436
17.1.2.4.2 Strategic choices 436
17.1.2.4.3 Weaknesses & competitive threats 436
17.1.3 ASYMCHEM INC. 437
17.1.3.1 Business overview 437
17.1.3.2 Products offered 438
17.1.3.3 Recent developments 439
17.1.3.3.1 Product launches 439
17.1.3.3.2 Expansions 439
17.1.3.3.3 Other developments 439
17.1.3.4 MnM view 440
17.1.3.4.1 Key strengths 440
17.1.3.4.2 Strategic choices 440
17.1.3.4.3 Weaknesses & competitive threats 440
17.1.4 CIPLA 441
17.1.4.1 Business overview 441
17.1.4.2 Products offered 442
17.1.4.3 Recent developments 443
17.1.4.3.1 Deals 443
17.1.4.3.2 Expansions 444
17.1.4.4 MnM view 444
17.1.4.4.1 Key strengths 444
17.1.4.4.2 Strategic choices 444
17.1.4.4.3 Weaknesses & competitive threats 445
17.1.5 EVONIK 446
17.1.5.1 Business overview 446
17.1.5.2 Products offered 447
17.1.5.3 Recent developments 448
17.1.5.3.1 Deals 448
17.1.5.3.2 Expansions 449
17.1.5.3.3 Other developments 449
17.1.5.4 MnM view 450
17.1.5.4.1 Key strengths 450
17.1.5.4.2 Strategic choices 450
17.1.5.4.3 Weaknesses & competitive threats 450
17.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 451
17.1.6.1 Business overview 451
17.1.6.2 Products offered 452
17.1.6.3 Recent developments 459
17.1.6.3.1 Product launches & approvals 459
17.1.6.3.2 Other developments 460
17.1.7 SANDOZ GROUP AG 461
17.1.7.1 Business overview 461
17.1.7.2 Products offered 462
17.1.7.3 Recent developments 463
17.1.7.3.1 Deals 463
17.1.7.3.2 Expansions 464
17.1.7.3.3 Other developments 465
17.1.8 SK INC. 466
17.1.8.1 Business overview 466
17.1.8.2 Products offered 467
17.1.8.3 Recent developments 468
17.1.8.3.1 Deals 468
17.1.8.3.2 Expansions 468
17.1.9 MERCK KGAA 469
17.1.9.1 Business overview 469
17.1.9.2 Products offered 470
17.1.9.3 Recent developments 471
17.1.9.3.1 Deals 471
17.1.10 DR. REDDY’S LABORATORIES LTD. 472
17.1.10.1 Business overview 472
17.1.10.2 Products offered 473
17.1.10.3 Recent developments 474
17.1.10.3.1 Deals 474
17.1.10.3.2 Expansions 475
17.1.10.3.3 Other developments 475
17.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD. 476
17.1.11.1 Business overview 476
17.1.11.2 Products offered 477
17.1.11.3 Recent developments 479
17.1.11.3.1 Deals 479
17.1.12 AUROBINDO PHARMA LIMITED 480
17.1.12.1 Business overview 480
17.1.12.2 Products offered 481
17.1.12.3 Recent developments 482
17.1.12.3.1 Deals 482
17.1.13 HIKMA PHARMACEUTICALS PLC 483
17.1.13.1 Business overview 483
17.1.13.2 Products offered 484
17.1.13.3 Recent developments 485
17.1.13.3.1 Expansions 485
17.1.14 BASF 486
17.1.14.1 Business overview 486
17.1.14.2 Products offered 487
17.1.14.3 Recent developments 488
17.1.14.3.1 Other developments 488
17.1.15 ALEMBIC PHARMACEUTICALS LIMITED 489
17.1.15.1 Business overview 489
17.1.15.2 Products offered 490
17.1.15.3 Recent developments 491
17.1.15.3.1 Product approvals 491
17.1.15.3.2 Other developments 491
17.1.16 SIEGFRIED HOLDING AG 492
17.1.16.1 Business overview 492
17.1.16.2 Products offered 493
17.1.16.3 Recent developments 494
17.1.16.3.1 Deals 494
17.1.16.3.2 Expansions 495
17.1.17 EUROAPI 496
17.1.17.1 Business overview 496
17.1.17.2 Products offered 497
17.1.17.3 Recent developments 497
17.1.17.3.1 Product launches 497
17.1.17.3.2 Deals 498
17.1.17.3.3 Expansions 498
17.1.18 BACHEM 499
17.1.18.1 Business overview 499
17.1.18.2 Products offered 500
17.1.18.3 Recent developments 501
17.1.18.3.1 Deals 501
17.1.18.3.2 Expansions 501
17.1.18.3.3 Other Deals 502
17.1.19 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. 503
17.1.19.1 Business overview 503
17.1.19.2 Products offered 503
17.1.20 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. 505
17.1.20.1 Business overview 505
17.1.20.2 Products offered 505
17.2 OTHER PLAYERS 506
17.2.1 POLYPEPTIDE GROUP 506
17.2.2 GRANULES INDIA 507
17.2.3 CORDEN PHARMA 508
17.2.4 RECIPHARM 509
17.2.5 ABURAIHAN PHARMACEUTICAL COMPANY 510
17.2.6 CURIA GLOBAL, INC. 511
17.2.7 CAMBREX CORPORATION 512
17.2.8 API PHARMA TECH 513
17.2.9 SREEPATHI PHARMACEUTICALS LIMITED 514
17.2.10 SHILPA MEDICARE LIMITED 515
17.2.11 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD. 516
17.2.12 HOVIONE 517
17.2.13 CHEMCON GMBH 518
17.2.14 PHARCO PHARMACEUTICALS 518
17.2.15 SAMBI PHARMA PVT. LTD. 519

18 RESEARCH METHODOLOGY 520
18.1 RESEARCH DATA 520
18.1.1 SECONDARY DATA 521
18.1.1.1 Key data from secondary sources 521
18.1.2 PRIMARY DATA 521
18.1.2.1 Key data from primary sources 521
18.1.2.2 Key primary participants 522
18.1.2.3 Breakdown of primary interviews 522
18.1.2.4 Key industry insights 523
18.2 MARKET SIZE ESTIMATION 524
18.2.1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ESTIMATION, 2025 524
18.2.2 SEGMENTAL MARKET SIZE ESTIMATION 527
18.3 MARKET GROWTH RATE PROJECTIONS 528
18.4 DATA TRIANGULATION 529
18.5 FACTOR ANALYSIS 530
18.6 RESEARCH ASSUMPTIONS 530
18.7 RESEARCH LIMITATIONS & RISK ASSESSMENT 531

19 APPENDIX 532
19.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 536
19.2 CUSTOMIZATION OPTIONS 538
19.3 RELATED REPORTS 538
19.4 AUTHOR DETAILS 539

ページTOPに戻る



List of Tables/Graphs

FIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & REGIONAL SCOPE 46.
FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED 47.
FIGURE 3 MARKET SCENARIO 50.
FIGURE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2024–2031 51.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2023–2026 51.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 52.
FIGURE 7 HIGH-GROWTH SEGMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2026–2031 53.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 54.
FIGURE 9 RISING DEMAND FOR INNOVATIVE, GENERIC, COMPLEX, AND BIOTECH APIS TO DRIVE MARKET GROWTH 55.
FIGURE 10 INNOVATIVE APIS ACCOUNTED FOR LARGEST SHARE OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN NORTH AMERICA IN 2025 56.
FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING FORECAST PERIOD 57.
FIGURE 12 TRADITIONAL APIS TO DOMINATE MARKET DURING FORECAST PERIOD 57.
FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58.
FIGURE 14 GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030 (USD BILLION) 61.
FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 70.
FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS 74.
FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS 75.
FIGURE 18 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,.
BY TYPE, 2025 77.
FIGURE 19 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,.
BY REGION, 2025 78.
FIGURE 20 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80.
FIGURE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT & FUNDING SCENARIO, 2025 (USD MILLION) 81.
FIGURE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES 91.
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 101.
FIGURE 24 KEY BUYING CRITERIA FOR END USERS 102.
FIGURE 25 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 256.
FIGURE 26 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 311.
FIGURE 27 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2025 (USD MILLION) 408.
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2025 409.
FIGURE 29 EV/EBITDA OF KEY VENDORS 411.
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 412.
FIGURE 31 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON 413.
FIGURE 32 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 415.
FIGURE 33 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT 416.
FIGURE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 422.
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2025) 429.
FIGURE 36 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2025) 432.
FIGURE 37 ASYMCHEM INC.: COMPANY SNAPSHOT (2025) 438.
FIGURE 38 CIPLA: COMPANY SNAPSHOT (2025) 442.
FIGURE 39 EVONIK: COMPANY SNAPSHOT (2025) 447.
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 451.
FIGURE 41 SANDOZ GROUP AG: COMPANY SNAPSHOT (2025) 462.
FIGURE 42 SK INC.: COMPANY SNAPSHOT (2025) 467.
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 470.
FIGURE 44 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2025) 473.
FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 477.
FIGURE 46 AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2025) 481.
FIGURE 47 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 484.
FIGURE 48 BASF: COMPANY SNAPSHOT (2025) 487.
FIGURE 49 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2025) 490.
FIGURE 50 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2025) 493.
FIGURE 51 EUROAPI: COMPANY SNAPSHOT (2025) 496.
FIGURE 52 BACHEM: COMPANY SNAPSHOT (2025) 500.
FIGURE 53 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN 520.
FIGURE 54 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF PRIMARIES 522.
FIGURE 55 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INSIGHTS FROM PRIMARIES 523.
FIGURE 56 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ESTIMATION, 2025 524.
FIGURE 57 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 525.
FIGURE 58 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE ANALYSIS (2025) 525.
FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 527.
FIGURE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS 528.
FIGURE 61 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION 529.
TABLE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS & EXCLUSIONS 47.
TABLE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 59.
TABLE 3 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2024 62.
TABLE 4 EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024 63.
TABLE 5 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,.
2023–2030 (USD BILLION) 68.
TABLE 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES 70.
TABLE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM 75.
TABLE 8 INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER, 2025 (USD) 77.
TABLE 9 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,.
BY REGION, 2025 (USD) 78.
TABLE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 79.
TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS 82.
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 83.
TABLE 13 KEY COMPANIES IMPLEMENTING AI 92.
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94.
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94.
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95.
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95.
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 96.
TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 102.
TABLE 20 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER 103.
TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,.
2023–2031 (USD BILLION) 107.
TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 107.
TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,.
2023–2031 (USD BILLION) 108.
TABLE 24 INNOVATIVE APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 109.
TABLE 25 NORTH AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 109.
TABLE 26 EUROPE: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110.
TABLE 27 ASIA PACIFIC: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110.
TABLE 28 LATIN AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 111.
TABLE 29 MIDDLE EAST: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 111.
TABLE 30 GCC COUNTRIES: INNOVATIVE APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 111.
TABLE 31 GENERIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 112.
TABLE 32 NORTH AMERICA: GENERIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 113.
TABLE 33 EUROPE: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 113.
TABLE 34 ASIA PACIFIC: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114.
TABLE 35 LATIN AMERICA: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114.
TABLE 36 MIDDLE EAST: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114.
TABLE 37 GCC COUNTRIES: GENERIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 115.
TABLE 38 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,.
2023–2031 (USD BILLION) 117.
TABLE 39 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 117.
TABLE 40 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,.
2023–2031 (USD BILLION) 118.
TABLE 41 TRADITIONAL APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 119.
TABLE 42 NORTH AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 119.
TABLE 43 EUROPE: TRADITIONAL APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 120.
TABLE 44 ASIA PACIFIC: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 120.
TABLE 45 LATIN AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 121.
TABLE 46 MIDDLE EAST: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 121.
TABLE 47 GCC COUNTRIES: TRADITIONAL APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 121.
TABLE 48 HIGHLY POTENT APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 122.
TABLE 49 HIGHLY POTENT APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 122.
TABLE 50 NORTH AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 123.
TABLE 51 EUROPE: HIGHLY POTENT APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 123.
TABLE 52 ASIA PACIFIC: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 124.
TABLE 53 LATIN AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 124.
TABLE 54 MIDDLE EAST: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 124.
TABLE 55 GCC COUNTRIES: HIGHLY POTENT APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 125.
TABLE 56 SYNTHETIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 126.
TABLE 57 NORTH AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 126.
TABLE 58 EUROPE: SYNTHETIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 127.
TABLE 59 ASIA PACIFIC: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 127.
TABLE 60 LATIN AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 128.
TABLE 61 MIDDLE EAST: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 128.
TABLE 62 GCC COUNTRIES: SYNTHETIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 128.
TABLE 63 BIOLOGIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 129.
TABLE 64 NORTH AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 130.
TABLE 65 EUROPE: BIOLOGIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 130.
TABLE 66 ASIA PACIFIC: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 131.
TABLE 67 LATIN AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 131.
TABLE 68 MIDDLE EAST: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 131.
TABLE 69 GCC COUNTRIES: BIOLOGIC HPAPIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 132.
TABLE 70 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,.
2023–2031 (USD BILLION) 134.
TABLE 71 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 134.
TABLE 72 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2031 (USD BILLION) 135.
TABLE 73 SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 136.
TABLE 74 NORTH AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 136.
TABLE 75 EUROPE: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137.
TABLE 76 ASIA PACIFIC: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137.
TABLE 77 LATIN AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 138.
TABLE 78 MIDDLE EAST: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 138.
TABLE 79 GCC COUNTRIES: SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 138.
TABLE 80 SYNTHETIC APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 139.
TABLE 81 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 140.
TABLE 82 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 140.
TABLE 83 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 141.
TABLE 84 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 141.
TABLE 85 LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 142.
TABLE 86 MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 142.
TABLE 87 GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 142.
TABLE 88 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 143.
TABLE 89 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 143.
TABLE 90 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 144.
TABLE 91 ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 144.
TABLE 92 LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 145.
TABLE 93 MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 145.
TABLE 94 GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 145.
TABLE 95 BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 146.
TABLE 96 NORTH AMERICA: BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 147.
TABLE 97 EUROPE: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 147.
TABLE 98 ASIA PACIFIC: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148.
TABLE 99 LATIN AMERICA: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148.
TABLE 100 MIDDLE EAST: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148.
TABLE 101 GCC COUNTRIES: BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 149.
TABLE 102 BIOTECH APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 149.
TABLE 103 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 150.
TABLE 104 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 150.
TABLE 105 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 151.
TABLE 106 ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 151.
TABLE 107 LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 152.
TABLE 108 MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 152.
TABLE 109 GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 152.
TABLE 110 GENERIC BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 154.
TABLE 111 NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 154.
TABLE 112 EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 155.
TABLE 113 ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 155.
TABLE 114 LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 156.
TABLE 115 MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 156.
TABLE 116 GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY,.
2023–2031 (USD BILLION) 156.
TABLE 117 BIOTECH APIS MARKET, BY PRODUCT, 2023–2031 (USD BILLION) 157.
TABLE 118 BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,.
2023–2031 (USD BILLION) 158.
TABLE 119 NORTH AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 158.
TABLE 120 EUROPE: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD BILLION) 159.
TABLE 121 ASIA PACIFIC: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 159.
TABLE 122 LATIN AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 160.
TABLE 123 MIDDLE EAST: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 160.
TABLE 124 GCC COUNTRIES: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,.
BY COUNTRY, 2023–2031 (USD BILLION) 160.
TABLE 125 BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2023–2031 (USD BILLION) 161.
TABLE 126 NORTH AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 161.
TABLE 127 EUROPE: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,.
BY COUNTRY, 2023–2031 (USD BILLION) 162.
TABLE 128 ASIA PACIFIC: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,.
BY COUNTRY, 2023–2031 (USD BILLION) 162.
TABLE 129 LATIN AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163.
TABLE 130 MIDDLE EAST: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,.
BY COUNTRY, 2023–2031 (USD BILLION) 163.
TABLE 131 GCC COUNTRIES: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163.
TABLE 132 BIOTECH APIS MARKET FOR FUSION PROTEINS, BY REGION,.
2023–2031 (USD BILLION) 164.
TABLE 133 NORTH AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 164.
TABLE 134 EUROPE: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY,.
2023–2031 (USD BILLION) 165.
TABLE 135 ASIA PACIFIC: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 165.
TABLE 136 LATIN AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166.
TABLE 137 MIDDLE EAST: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166.
TABLE 138 GCC COUNTRIES: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166.
TABLE 139 BIOTECH APIS MARKET FOR CYTOKINES, BY REGION, 2023–2031 (USD BILLION) 167.
TABLE 140 NORTH AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 167.
TABLE 141 EUROPE: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 168.
TABLE 142 ASIA PACIFIC: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 168.
TABLE 143 LATIN AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 169.
TABLE 144 MIDDLE EAST: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 169.
TABLE 145 GCC COUNTRIES: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,.
2023–2031 (USD BILLION) 169.
TABLE 146 BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY REGION,.
2023–2031 (USD BILLION) 170.
TABLE 147 NORTH AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,.
BY COUNTRY, 2023–2031 (USD BILLION) 170.
TABLE 148 EUROPE: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171.
TABLE 149 ASIA PACIFIC: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171.
TABLE 150 LATIN AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,.
BY COUNTRY, 2023–2031 (USD BILLION) 172.
TABLE 151 MIDDLE EAST: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 172.
TABLE 152 GCC COUNTRIES: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,.
BY COUNTRY, 2023–2031 (USD BILLION) 172.
TABLE 153 BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY REGION, 2023–2031 (USD BILLION) 173.
TABLE 154 NORTH AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 173.
TABLE 155 EUROPE: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS,.
BY COUNTRY, 2023–2031 (USD BILLION) 174.
TABLE 156 ASIA PACIFIC: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 174.
TABLE 157 LATIN AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175.
TABLE 158 MIDDLE EAST: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175.
TABLE 159 GCC COUNTRIES: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175.
TABLE 160 BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY REGION,.
2023–2031 (USD BILLION) 176.
TABLE 161 NORTH AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 177.
TABLE 162 EUROPE: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 177.
TABLE 163 ASIA PACIFIC: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 178.
TABLE 164 LATIN AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 178.
TABLE 165 MIDDLE EAST: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 179.
TABLE 166 GCC COUNTRIES: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,.
BY COUNTRY, 2023–2031 (USD BILLION) 179.
TABLE 167 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM, 2023–2031 (USD BILLION) 180.
TABLE 168 BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 181.
TABLE 169 NORTH AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 181.
TABLE 170 EUROPE: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 182.
TABLE 171 ASIA PACIFIC: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 182.
TABLE 172 LATIN AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183.
TABLE 173 MIDDLE EAST: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183.
TABLE 174 GCC COUNTRIES: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183.
TABLE 175 BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 184.
TABLE 176 NORTH AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 185.
TABLE 177 EUROPE: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 185.
TABLE 178 ASIA PACIFIC: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 186.
TABLE 179 LATIN AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 186.
TABLE 180 MIDDLE EAST: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 187.
TABLE 181 GCC COUNTRIES: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 187.
TABLE 182 BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION,.
2023–2031 (USD BILLION) 188.
TABLE 183 NORTH AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 188.
TABLE 184 EUROPE: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 189.
TABLE 185 ASIA PACIFIC: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 189.
TABLE 186 LATIN AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 190.
TABLE 187 MIDDLE EAST: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 190.
TABLE 188 GCC COUNTRIES: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 190.
TABLE 189 BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION,.
2023–2031 (USD BILLION) 192.
TABLE 190 NORTH AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 192.
TABLE 191 EUROPE: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 193.
TABLE 192 ASIA PACIFIC: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 193.
TABLE 193 LATIN AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 194.
TABLE 194 MIDDLE EAST: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 194.
TABLE 195 GCC COUNTRIES: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 194.
TABLE 196 BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION,.
2023–2031 (USD BILLION) 195.
TABLE 197 NORTH AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 195.
TABLE 198 EUROPE: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 196.
TABLE 199 ASIA PACIFIC: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 196.
TABLE 200 LATIN AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 197.
TABLE 201 MIDDLE EAST: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 197.
TABLE 202 GCC COUNTRIES: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,.
BY COUNTRY, 2023–2031 (USD BILLION) 197.
TABLE 203 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,.
2023–2031 (USD BILLION) 199.
TABLE 204 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 199.
TABLE 205 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2031 (USD BILLION) 200.
TABLE 206 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS,.
BY REGION, 2023–2031 (USD BILLION) 201.
TABLE 207 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 201.
TABLE 208 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202.
TABLE 209 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202.
TABLE 210 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203.
TABLE 211 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203.
TABLE 212 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203.
TABLE 213 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2031 (USD BILLION) 204.
TABLE 214 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205.
TABLE 215 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205.
TABLE 216 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206.
TABLE 217 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206.
TABLE 218 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207.
TABLE 219 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207.
TABLE 220 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 209.
TABLE 221 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 210.
TABLE 222 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 210.
TABLE 223 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2031 (USD BILLION) 211.
TABLE 224 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212.
TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212.
TABLE 226 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213.
TABLE 227 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213.
TABLE 228 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214.
TABLE 229 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214.
TABLE 230 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER 215.
TABLE 231 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2023–2031 (USD BILLION) 215.
TABLE 232 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 216.
TABLE 233 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,.
BY COUNTRY, 2023–2031 (USD BILLION) 216.
TABLE 234 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217.
TABLE 235 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217.
TABLE 236 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218.
TABLE 237 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218.
TABLE 238 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2023–2031 (USD BILLION) 219.
TABLE 239 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 219.
TABLE 240 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,.
BY COUNTRY, 2023–2031 (USD BILLION) 220.
TABLE 241 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 220.
TABLE 242 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221.
TABLE 243 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221.
TABLE 244 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221.
TABLE 245 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD BILLION) 222.
TABLE 246 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223.
TABLE 247 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223.
TABLE 248 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224.
TABLE 249 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224.
TABLE 250 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225.
TABLE 251 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225.
TABLE 252 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2031 (USD BILLION) 226.
TABLE 253 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 226.
TABLE 254 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227.
TABLE 255 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227.
TABLE 256 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228.
TABLE 257 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228.
TABLE 258 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228.
TABLE 259 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT,.
BY REGION, 2023–2031 (USD BILLION) 229.
TABLE 260 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230.
TABLE 261 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230.
TABLE 262 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231.
TABLE 263 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231.
TABLE 264 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232.
TABLE 265 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232.
TABLE 266 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2031 (USD BILLION) 233.
TABLE 267 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD BILLION) 233.

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

MarketsandMarkets社の Pharmaceuticals分野 での最新刊レポート

本レポートと同じKEY WORD(active pharmaceutical)の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/19 10:27

160.48 円

176.53 円

213.76 円

ページTOPに戻る